Beijing Konruns Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 10.55%

Beijing Konruns Pharmaceutical Co Ltd (603590) has an Asset Resilience Ratio of 10.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥430.11 Million

≈ $62.94 Million USD Cash + Short-term Investments

Total Assets

CN¥4.08 Billion

≈ $596.62 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Beijing Konruns Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Beijing Konruns Pharmaceutical Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥430.11 Million	10.55%
Total Liquid Assets	CN¥430.11 Million	10.55%

Asset Resilience Insights

Moderate Liquidity: Beijing Konruns Pharmaceutical Co Ltd has 10.55% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Beijing Konruns Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Konruns Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Beijing Konruns Pharmaceutical Co Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Konruns Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.22%	CN¥500.43 Million ≈ $73.23 Million	CN¥4.09 Billion ≈ $599.23 Million	+0.72pp
2024-12-31	11.50%	CN¥450.66 Million ≈ $65.95 Million	CN¥3.92 Billion ≈ $573.57 Million	+1.01pp
2023-12-31	10.48%	CN¥396.41 Million ≈ $58.01 Million	CN¥3.78 Billion ≈ $553.25 Million	+2.30pp
2022-12-31	8.19%	CN¥280.37 Million ≈ $41.03 Million	CN¥3.42 Billion ≈ $501.16 Million	+7.92pp
2021-12-31	0.27%	CN¥9.04 Million ≈ $1.32 Million	CN¥3.37 Billion ≈ $493.33 Million	-4.52pp
2020-12-31	4.79%	CN¥181.36 Million ≈ $26.54 Million	CN¥3.79 Billion ≈ $553.96 Million	+4.73pp
2019-12-31	0.06%	CN¥2.00 Million ≈ $293.16K	CN¥3.17 Billion ≈ $464.43 Million	--

pp = percentage points

About Beijing Konruns Pharmaceutical Co Ltd

SHG:603590 China Biotechnology

Market Cap

$692.46 Million

CN¥4.73 Billion CNY

Market Cap Rank

#10418 Global

#2744 in China

Share Price

CN¥29.76

Change (1 day)

+0.88%

52-Week Range

CN¥28.13 - CN¥62.00

All Time High

CN¥65.00